Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy
Executive Summary
The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.
You may also be interested in...
Rigel Ready To Hit The Ground Running After Early AML Drug Approval
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.
Tibsovo Gets A Win In AML Following Servier Takeover
Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.